
The FDA has rejected BioMarin’s Duchenne Muscular Dystrophy (DMD) drug Kyndrisa, saying there was not enough evidence that the drug …

Rare-disease drug firm BioMarin has finalised its purchase of muscular disease specialist Prosensa in a deal worth over $840 million. …

An experimental treatment by GSK and Prosensa for a rare type of muscle-degenerating disease has failed to meet its primary …

